Format

Send to

Choose Destination
Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6.

Obtaining real-world evidence: the Salford Lung Study.

Author information

1
Salford Royal NHS Foundation Trust, Salford, UK.
2
GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex, UK.
3
Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Erratum in

Abstract

We need to assess clinical treatments in real-life settings outside of randomised controlled trials (RCTs). Pragmatic RCT (pRCT) data can supplement RCTs by providing effectiveness information to support healthcare decisions. Electronic health records can facilitate concurrent safety monitoring and data collection without direct patient contact for large randomised study populations in pRCTs. The Salford Lung Study is the world's first phase III pRCT in asthma and chronic obstructive pulmonary disease (COPD), which aims to randomise over 7000 patients. This paper describes the hurdles overcome and the enormous effort and resource required to establish this comparative effectiveness study of a prelicence intervention.

GLAXOSMITHKLINE PROTOCOL:

HZC115151 ASTHMA STUDY CLINICALTRIALSGOV REGISTRATION: NCT01706198 COPD STUDY CLINICALTRIALSGOV REGISTRATION: NCT01551758.

KEYWORDS:

Asthma; COPD Exacerbations

PMID:
24603195
PMCID:
PMC4251297
DOI:
10.1136/thoraxjnl-2014-205259
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center